InnaVirVax, an Evry, France-based biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, has closed a €3.7m (approximately $4.9m) Series B funding round.
The round has been led by Pradeyrol Développement and private equity funds Fa Dièse and Fonds Régional de Co-Investissement d’Ile-de-France (FRCI), with participation from existing investors CapDecisif 2 and G1J Ile-de-France.
Incorporated in 2008, and led by CEO Joël Crouzet, InnaVirVax is dedicated to the development of solutions in the field of therapy/prevention and prognostic of AIDS and HIV infection, other infectious diseases, and new cancer therapies.
The company intends to use the capital to conduct the phase I/IIa clinical trials of VAC-3S immunotherapy (which will be carried out in two clinical centers of the Assistance Publique – Hôpitaux de Paris, namely the Pitié Salpêtrière and Cochin Hospitals), as well as develop other research projects. VAC-3S already received the authorization from the AFSSAPS (the French Drug Agency).